These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11211913)

  • 1. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity.
    Ginsber GM; Slater PE; Shouval D
    J Hepatol; 2001 Jan; 34(1):92-9. PubMed ID: 11211913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Shouval D
    J Epidemiol Community Health; 1992 Dec; 46(6):587-94. PubMed ID: 1494073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Berger S; Shouval D
    Bull World Health Organ; 1992; 70(6):757-67. PubMed ID: 1486673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost containment analysis of childhood vaccination against varicella in Israel.
    Ginsberg GM; Somekh E
    J Infect; 2004 Feb; 48(2):119-33. PubMed ID: 14720487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.
    Carlos F; Gómez JA; Anaya P; Romano-Mazzotti L
    Hum Vaccin Immunother; 2016; 12(1):52-63. PubMed ID: 26503702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context.
    Sartori AM; de Soárez PC; Novaes HM; Amaku M; de Azevedo RS; Moreira RC; Pereira LM; Ximenes RA; Martelli CM
    Vaccine; 2012 Dec; 30(52):7489-97. PubMed ID: 23107593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach.
    Hayajneh WA; Daniels VJ; James CK; Kanıbir MN; Pilsbury M; Marks M; Goveia MG; Elbasha EH; Dasbach E; Acosta CJ
    BMC Infect Dis; 2018 Mar; 18(1):119. PubMed ID: 29514609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].
    Pan XJ; Feng YM; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):862-6. PubMed ID: 22967346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of active vaccination campaigns against hepatitis A among daycare centre personnel in Israel.
    Chodick G; Lerman Y; Peled T; Aloni H; Ashkenazi S
    Pharmacoeconomics; 2001; 19(3):281-91. PubMed ID: 11303416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.
    Ginsberg GM; Kassis I; Dagan R
    J Epidemiol Community Health; 1993 Dec; 47(6):485-90. PubMed ID: 8120505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
    Valenzuela MT; Jacobs RJ; Arteaga O; Navarrete MS; Meyerhoff AS; Innis BL
    Vaccine; 2005 Jul; 23(32):4110-9. PubMed ID: 15964479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries.
    Das A
    Hepatology; 1999 Feb; 29(2):548-52. PubMed ID: 9918934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands).
    Postma MJ; Bos JM; Beutels P; Schilthuis H; van den Hoek JA
    Vaccine; 2004 May; 22(15-16):1862-7. PubMed ID: 15121296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States.
    Rein DB; Hicks KA; Wirth KE; Billah K; Finelli L; Fiore AE; Hoerger TJ; Bell BP; Armstrong GL
    Pediatrics; 2007 Jan; 119(1):e12-21. PubMed ID: 17200237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A.
    Jacobs RJ; Koff RS; Meyerhoff AS
    Am J Gastroenterol; 2002 Feb; 97(2):427-34. PubMed ID: 11866283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of vaccination against hepatitis A in travellers.
    Van Doorslaer E; Tormans G; Van Damme P
    J Med Virol; 1994 Dec; 44(4):463-9. PubMed ID: 7897383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza.
    Ginsberg GM; Tulchinsky TH
    J Epidemiol Community Health; 1990 Dec; 44(4):274-80. PubMed ID: 2126028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China.
    Zhuang GH; Pan XJ; Wang XL
    Vaccine; 2008 Aug; 26(35):4608-16. PubMed ID: 18597903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis.
    Gillis D; Yetiv N; Gdalevich M; Mimouni D; Ashkenazi I; Shpilberg O; Eldad A; Shemer J
    Vaccine; 2000 Jul; 18(26):3005-10. PubMed ID: 10825603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.